AVIR News and Press, Atea Pharmaceuticals Inc. From 11/29/22

Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of Bemnifosbuvir Supported by Clinical Data from Late-Stage MORNINGSKY Trial and Prior S...

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members ...

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will participate in and pres...

Atea Pharmaceuticals, Inc. (AVIR) Q3 2022 Earnings Conference Call November 07, 2022 04:30 PM ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - CEO and Founder John Vavricka - CCO Janet Hammond - CDO An...

The following slide deck was published by Atea Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Atea Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation

Atea Pharmaceuticals press release ( NASDAQ: AVIR ): Q3 GAAP EPS of -$0.10 beats by $0.34 . Cash, Cash Equivalents and Marketable Securities: $665.0 million at September 30, 2022 compared to $764.4 million at December 31, 2021. For further details see: Atea P...

Enrollment of SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 Expected Before Year-End 2022 Completion of Patient Enrollment Expected Around Year-End 2022 for AT-752 U.S. Human Challenge Study and for First Coho...

Atea Pharmaceuticals ( NASDAQ: AVIR ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open. The consensus EPS Estimate is -$0.44 (-29.4% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2...

Safety and pharmacokinetic data in healthy volunteers support ongoing clinical development AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development with a Fast Track designation from the U.S. Food and Drug Administration for treatment of dengue ...

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report financial...